

Haploidentical stem cell transplantation for paediatric patients with thalassemia major

Submission date 04/08/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/08/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 08/02/2021	Condition category Haematological Disorders	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims:

Thalassemia major (or beta-thalassemia) is a genetic disorder in which there are abnormal beta haemoglobin chains in red blood cells. Patients with thalassemia major require lifelong blood transfusions for survival, but these may bring complications including iron overload, failure to thrive, or transfusion-transmitted infections. Hematopoietic stem cells are the stem cells that give rise to other blood cells. Haematopoietic stem cell transplantation (HSCT) is currently the only cure for thalassemia major. Although alternative donors have greatly improved the choice of donors for thalassemia major patients, long-term safety and effectiveness varies between different protocols. The aim of this study is to investigate the outcomes of thalassemia major patients who received HSCT using a newly developed protocol with alternative donors.

Who can participate?

Patients aged 2 to 18 who have been diagnosed with thalassemia major and have indications for haematopoietic stem cell transplantation

What does the study involve?

All participants receive HSCT using a newly developed protocol with alternative donors. The duration of the treatment will be about 1 year but can be longer depending on the condition of the patient. The follow-up time will be at least 2 years after the transplant but the researchers expect to follow the patients as long as possible.

What are the possible benefits and risks of participating?

The recruited patients will be given the information at the time of recruitment.

Where is the study run from?

Shenzhen Children's Hospital (China)

When is the study starting and how long is it expected to run for?

August 2020 to August 2023

Who is funding the study?

1. Shenzhen Key Medical Discipline Construction Fund (China)

2. Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (China)
3. Sanming Project of Medicine in Shenzhen (China)

Who is the main contact?

Dr Uet Yu

cloveringo69@hotmail.com

Contact information

Type(s)

Scientific

Contact name

Dr Sixi Liu

Contact details

7019 Yitian Road

Futian

Shenzhen

China

518038

+86 (0)18938690206

tiger647@126.com

Type(s)

Public

Contact name

Dr Uet Yu

Contact details

7019 Yitian Road

Futian

Shenzhen

China

518038

+86 (0)13622311888

cloveringo69@hotmail.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Study information

Scientific Title

Combined haematopoietic stem cell transplantation with haploidentical graft and cord blood for paediatric patients with thalassemia major: a single centre, prospective study (SZTM2020)

Acronym

SZTM2020

Study objectives

This study is to study the outcomes of patients with thalassemia major who received haematopoietic stem cell transplantation using a protocol developed for haploidentical donors. The primary hypothesis is that this protocol will promote stable engraftment of hematopoietic cells, support normal erythropoiesis, prevent severe graft versus host diseases, life-threatening infections, and other severe transplant-related complications, and result in an event-free survival of > 90% of children with thalassemia major.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 28/01/2021, Shenzhen Children's Hospital Ethics Committee (Shenzhen Children's Hospital, 7019 Yitian Road, Futian, Shenzhen, China; +86 (0)755 8300 8379; seyllwyh@163.com), ref: 202000302

Study design

Non-randomised single-centre study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not applicable

Health condition(s) or problem(s) studied

Thalassemia major

Interventions

Conditioning chemotherapy:

1. Cyclophosphamide (CY, 50 mg/kg/day x 2 days, day -8 to -7)
2. Busulfan (BU, 2.8-4.4 mg/kg/day x 3 days, day -6 to -4)
*The dose of BU is determined based on risk assessments of thalassemia patients and adjusted according to pharmacokinetic evaluation after the seventh dose of BU.
3. Fludarabine (FLU, 40 mg/m²/day x 5 days, day -6 to -2)
4. Anti-thymoglobulin (ATG, 1 mg/kg/day x 3 days, day -3 to -1)
5. Thiotepa (TT, 5 mg/kg/dose x 2 doses at 12 h interval, day -3)

Cell transfusions:

D0: Bone marrow (BM) and/or peripheral blood stem cell (PBSC)

D1: Umbilical cord blood (UCB) and/or peripheral blood stem cell (PBSC)

*Cell dose: A total of up to 20×10^8 /kg mononuclear cells (MNCs) for patients with negative results for donor-specific antigen (DSA) before transplant. A total of up to 25×10^8 /kg MNCs for patients with positive DSA results before transplant.

Prophylaxis for graft versus host diseases:

1. Cyclophosphamide (CY, 50 mg/kg/day x 2 days, day +3 to +4)
2. Tacrolimus (FK506, 0.04 mg/kg/d, from day +5)
* The dose of FK506 is adjusted according to blood concentration.
3. Mycophenolate mofetil (MMF, 10 mg/kg/day, from day +5)

The duration from conditioning chemotherapy to the end of GVHD prophylaxis will take approximately 1 year but can be longer depending on the condition of the patient. The follow-up time for patients recruited for this trial will be at least 2 years post-transplant but the researchers expect to follow the patients as long as possible.

Intervention Type

Mixed

Primary outcome measure

1. Overall survival (OS) using Kaplan-Meier estimator at 2 years
2. Thalassemia-free survival (TFS) using R at 2 years

Secondary outcome measures

1. Engraftment: myeloid engraftment (absolute neutrophils count $\geq 0.5 \times 10^9$ /L for 3 consecutive days) at day +30
2. Transplant-related mortality: using Kaplan-Meier estimator at 2 years
3. Cumulative incidence of acute graft versus host disease (GVHD): acute GVHD by day +180. The classification of aGVHD is determined using either Glucksberg scoring system or IBMTR scoring system
4. Cumulative incidence of chronic GVHD by 2 years. The classification of cGVHD is determined according to the overall severity chronic GVHD grading system
5. Cumulative incidence of sinusoidal obstruction syndrome (SOS, also known as hepatic veno-occlusive disease, VOD): cumulative incidence of SOS/VOD at day +180
6. Cumulative incidence of infectious complications: cumulative incidence of bacterial, fungal, and viral infections by 2 years

Overall study start date

01/08/2020

Completion date

31/08/2023

Eligibility

Key inclusion criteria

1. Age 2 to 18 years
2. Diagnosed with thalassemia major
3. Indication of haematopoietic stem cell transplantation
4. A cardiac ejection fraction of >50%; normal pulmonary function tests and pulmonary examination results; and normal kidney function

Participant type(s)

Patient

Age group

Child

Lower age limit

2 Years

Upper age limit

18 Years

Sex

Both

Target number of participants

200

Key exclusion criteria

1. Uncontrolled bacterial, viral, or fungal infections before transplant
2. Severe liver and heart overload: liver MR T2* value > 1.4 ms or heart MR T2* value > 10 ms
3. Any other restriction for transplant

Date of first enrolment

01/11/2020

Date of final enrolment

28/02/2023

Locations

Countries of recruitment

China

Study participating centre

Shenzhen Children's Hospital
7019 Yitian Road
Futian
Shenzhen
China
518038

Sponsor information

Organisation

Shenzhen Children's Hospital

Sponsor details

7019 Yitian Road
Futian
Shenzhen
China
518038
+86 (0)755-83009876
sz83936209@163.com

Sponsor type

Hospital/treatment centre

Website

<http://www.szkid.com.cn/>

ROR

<https://ror.org/0409k5a27>

Funder(s)

Funder type

Research organisation

Funder Name

Shenzhen Key Medical Discipline Construction Fund (SZXK034)

Funder Name

Sanming Project of Medicine in Shenzhen (SZSM201512033)

Funder Name

Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (SZGSP012)

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

30/08/2024

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

IPD sharing plan summary

Other